News
-
Scottish device developer 1nhaler has announced the closing of a £1.5 million funding led by Archangels, with proceeds intended for continued development the company’s disposable single-use dry powder inhaler. The company says that funds will… Read more . . .
-
Nebulizer maker Aerogen and inhaled interferon developer Synairgen have entered a strategic partnership for development of a custom device for delivery of Synairgen’s SNG001 inhaled interferon-beta, the companies have announced, noting that the new agreement… Read more . . .
-
According to Glenmark Pharmaceuticals, China’s National Medical Products Administration (NMPA) has approved Ryaltris olopatadine hydrochloride / mometasone furoate nasal spray for the treatment of allergic rhinitis. Grand Pharmaceuticals, which acquired the Chinese rights to Ryaltris… Read more . . .
-
MannKind Corporation announced that it has discontinued the Phase 3 ICoN-1 study of MNKD-101 nebulized clofazimine inhalation suspension for the treatment of nontuberculous mycobacterial (NTM) lung disease “due to futility” after analysis of data from the… Read more . . .
-
Chiesi has held an inauguration ceremony for an expanded manufacturing facility in La Chaussée-Saint-Victor, France where the company will manufacture metered dose inhalers with low global warming potential (LGWP) propellants, the company said. Earlier this… Read more . . .
-
Nasal vaccine developer CastleVax has announced the initiation of a Phase 2 study comparing its CVAX-01 intranasal COVID-19 vaccine to an mRNA-based injectable COVID-19 vaccine. The 6-month study is expected to enroll 200 previously-vaccinated adults… Read more . . .
-
Evoke Pharma, which developed and manufactures Gimoti intranasal metoclopramide, has agreed to be acquired by QOL Medical for $11 per share, the companies said. The FDA approved Gimoti for the treatment of diabetic gastroparesis in June 2020. Evoke… Read more . . .
-
Rein Therapeutics announced that the FDA has lifted a full clinical hold on the Phase 2 “RENEW” trial of the company’s LTI-03 inhaled dry powder caveolin-1-based peptide in patients with idiopathic pulmonary fibrosis (IPF). The… Read more . . .
-
Iconovo, which said earlier this year that it would discontinue internal development and would focus on commercialization of its existing DPI platforms, has announced that CEO Johan Wäborg will step down, and advisor Anders Månsson… Read more . . .
-
Ritedose Corporation announced that it licensed an ANDA for tobramycin inhalation solution from Hikma and that the FDA has approved the company to manufacture and distribute the product. The company noted that tobramycin, which is… Read more . . .
Upcoming Events
Sponsored by Intertek
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
May 10-May 14: RDD 2026, Phoenix, AZ, USA
May 15-May 16: ATS Respiratory Innovation Summit 2026, Orlando, FL, USA
May 17-May 20: ATS International Conference 2026, Orlando, FL, USA
June 9-June 10: Nasal Drug Delivery Symposium: Current Status and Future Opportunities, Stockholm, Sweden
June 10: SMI.London 2026, London, UK